$DAWN
Day One Biopharmaceuticals, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021003496 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.79M $9.392M $4.680M
YoY Change 130.47% 817.19% 363.37%
% of Gross Profit
Research & Development $11.19M $9.849M $9.100M
YoY Change 22.96% 288.21% -34.53%
% of Gross Profit
Depreciation & Amortization $5.000K $5.000K $10.00K
YoY Change -50.0% 0.0%
% of Gross Profit
Operating Expenses $21.98M $19.24M $13.78M
YoY Change 59.47% 440.33% -7.58%
Operating Profit -$19.24M
YoY Change 440.33%
Interest Expense $23.00K $6.000K -$30.03M
YoY Change -100.08% -33.33% 1343.75%
% of Operating Profit
Other Income/Expense, Net $14.00K $7.000K -$30.00K
YoY Change -146.67% -800.0%
Pretax Income -$21.94M -$19.24M -$43.84M
YoY Change -49.96% 400.78% 158.19%
Income Tax
% Of Pretax Income
Net Earnings -$21.94M -$19.24M -$40.51M
YoY Change -45.85% 400.78% 220.74%
Net Earnings / Revenue
Basic Earnings Per Share -$0.33
Diluted Earnings Per Share -$354.1K -$334.5K -$671.4K
COMMON SHARES
Basic Shares Outstanding 61.93M 57.51M
Diluted Shares Outstanding 57.51M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $284.3M $297.2M $43.73M
YoY Change 550.15% 60.01%
Cash & Equivalents $284.3M $297.2M $43.73M
Short-Term Investments
Other Short-Term Assets $289.4M $303.3M $45.07M
YoY Change 542.03% 450610.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $289.4M $303.3M $45.07M
YoY Change 542.03% 64.85%
LONG-TERM ASSETS
Property, Plant & Equipment $57.00K $62.00K $77.00K
YoY Change -25.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $169.0K $137.0K $110.0K
YoY Change 53.64%
Other Assets
YoY Change
Total Long-Term Assets $453.0K $472.0K $590.0K
YoY Change -23.22%
TOTAL ASSETS
Total Short-Term Assets $289.4M $303.3M $45.07M
Total Long-Term Assets $453.0K $472.0K $590.0K
Total Assets $289.8M $303.8M $45.66M
YoY Change 534.72% 67.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.744M $683.0K $202.0K
YoY Change 763.37% 188.57%
Accrued Expenses $6.709M $5.178M $1.596M
YoY Change 320.36% 239.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.657M $6.046M $1.996M
YoY Change 333.72% -1.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $16.00K $65.00K $200.0K
YoY Change -92.0%
Total Long-Term Liabilities $16.00K $65.00K $200.0K
YoY Change -92.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.657M $6.046M $1.996M
Total Long-Term Liabilities $16.00K $65.00K $200.0K
Total Liabilities $8.673M $6.111M $2.200M
YoY Change 294.23% -70.71%
SHAREHOLDERS EQUITY
Retained Earnings -$127.5M -$105.5M -$56.84M
YoY Change 124.28%
Common Stock $6.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $281.1M $297.7M -$54.21M
YoY Change
Total Liabilities & Shareholders Equity $289.8M $303.8M $45.66M
YoY Change 534.72% 67.01%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$21.94M -$19.24M -$40.51M
YoY Change -45.85% 400.78% 220.74%
Depreciation, Depletion And Amortization $5.000K $5.000K $10.00K
YoY Change -50.0% 0.0%
Cash From Operating Activities -$13.17M -$12.22M -$5.939M
YoY Change 121.74% 241.56% 31.39%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $3.000K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $3.000K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 318.0K -615.0K 29.98M
YoY Change -98.94% -3.01%
NET CHANGE
Cash From Operating Activities -13.17M -12.22M -5.939M
Cash From Investing Activities 0.000 0.000 3.000K
Cash From Financing Activities 318.0K -615.0K 29.98M
Net Change In Cash -12.85M -12.84M 24.04M
YoY Change -153.45% 258.75% -8.89%
FREE CASH FLOW
Cash From Operating Activities -$13.17M -$12.22M -$5.939M
Capital Expenditures $0.00 $0.00 $3.000K
Free Cash Flow -$13.17M -$12.22M -$5.942M
YoY Change 121.63% 241.56% 31.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
CY2021Q3 dawn Changes In Fair Value Of Derivative Tranches Liability
ChangesInFairValueOfDerivativeTranchesLiability
dei Amendment Flag
AmendmentFlag
false
us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
CY2021Q3 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43728000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6151000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
297160000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1343000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
303311000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q3 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
dawn Changes In Fair Value Of Derivative Tranches Liability
ChangesInFairValueOfDerivativeTranchesLiability
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001845337
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40431
dei Entity Registrant Name
EntityRegistrantName
DAY ONE BIOPHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2415215
dei Entity Address Address Line1
EntityAddressAddressLine1
395 Oyster Point Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 217
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
484-0899
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
DAWN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61928939
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
403214000
CY2021Q3 dawn Deferred Shares Par Value Per Shares
DeferredSharesParValuePerShares
0
CY2020Q4 dawn Deferred Shares Par Value Per Shares
DeferredSharesParValuePerShares
0
CY2021Q3 us-gaap Deferred Compensation Arrangement With Individual Shares Authorized For Issuance
DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
0
us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
0
CY2021Q3 dawn Deferred Shares Outstanding
DeferredSharesOutstanding
0
CY2020Q4 us-gaap Deferred Compensation Arrangement With Individual Shares Authorized For Issuance
DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
4312540
CY2020 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
4112012
CY2020Q4 dawn Deferred Shares Outstanding
DeferredSharesOutstanding
4112012
CY2020Q4 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
637000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45661000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9849000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2537000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32395000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4935000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
45071000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
62000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
77000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
273000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
406000
CY2021Q3 dawn Deposits And Other Longterm Assets Non Current
DepositsAndOtherLongtermAssetsNonCurrent
137000
CY2020Q4 dawn Deposits And Other Longterm Assets Non Current
DepositsAndOtherLongtermAssetsNonCurrent
107000
CY2021Q3 us-gaap Assets
Assets
303783000
CY2020Q4 us-gaap Assets
Assets
45661000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
683000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
202000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5161000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1596000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
202000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
198000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6046000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1996000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
65000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
204000
CY2021Q3 us-gaap Liabilities
Liabilities
6111000
CY2020Q4 us-gaap Liabilities
Liabilities
2200000
CY2020Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
91964000
CY2020Q4 us-gaap Redeemable Noncontrolling Interest Equity Other Carrying Amount
RedeemableNoncontrollingInterestEquityOtherCarryingAmount
5702000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105548000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56842000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
297672000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-54205000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
303783000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5149000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19240000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
297672000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-10673000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
59000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1535000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-54205000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
538000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15182000
dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-6130000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-68849000
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
221721000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
57000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.98
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57514218
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5601511
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29859883
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5456733
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9392000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1024000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18373000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2703000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
19241000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
3561000
us-gaap Operating Expenses
OperatingExpenses
50768000
us-gaap Operating Expenses
OperatingExpenses
7638000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19241000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3561000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50768000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7638000
CY2021Q3 us-gaap Interest Expense
InterestExpense
6000
CY2020Q3 us-gaap Interest Expense
InterestExpense
9000
us-gaap Interest Expense
InterestExpense
19000
us-gaap Interest Expense
InterestExpense
22000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2020Q3 dawn Changes In Fair Value Of Derivative Tranches Liability
ChangesInFairValueOfDerivativeTranchesLiability
-271000
dawn Changes In Fair Value Of Derivative Tranches Liability
ChangesInFairValueOfDerivativeTranchesLiability
-578000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-19240000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-3842000
us-gaap Profit Loss
ProfitLoss
-50816000
us-gaap Profit Loss
ProfitLoss
-8243000
CY2020Q3 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-1018000
us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-2109000
us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-2113000
us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
99994000
CY2021Q3 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-19240000
CY2020Q3 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-2824000
dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-148701000
CY2021Q2 dawn Conversion Of Redeemable Noncontrolling Interest To Common Stock Values
ConversionOfRedeemableNoncontrollingInterestToCommonStockValues
3592000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-12149000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
167045000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2537000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14284000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
311763000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-13852000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
60000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2824000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-16616000
us-gaap Profit Loss
ProfitLoss
-50816000
us-gaap Profit Loss
ProfitLoss
-8243000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
8000000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8224000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
176000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1760000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
133000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
96000
us-gaap Paid In Kind Interest
PaidInKindInterest
19000
us-gaap Paid In Kind Interest
PaidInKindInterest
22000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
578000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4808000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
615000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
31000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
71000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
483000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
303000
dawn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3565000
dawn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
316000
dawn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-154000
dawn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-123000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35370000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7551000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
93000
dawn Payments To Acquire Process Research And Development Assets
PaymentsToAcquireProcessResearchAndDevelopmentAssets
8000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-93000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
129757000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
167045000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
296802000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
253432000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7644000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43728000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27332000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
297160000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19688000
dawn Exchange Of Preferred Common And Incentive Shares In Connection With The Conversion
ExchangeOfPreferredCommonAndIncentiveSharesInConnectionWithTheConversion
224892000
dawn Exchange Of Redeemable Convertible Noncontrolling Interest To Shares Of Common Stock
ExchangeOfRedeemableConvertibleNoncontrollingInterestToSharesOfCommonStock
3592000
dawn Right Of Use Asset Capitalization
RightOfUseAssetCapitalization
545000
CY2021Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
167000000.0
CY2021Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
17000000.0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
4719605
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
2.325-for-1
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105500000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
297200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, the fair value of the redeemable convertible preferred shares, the fair value of the common shares, the fair value of the derivative tranche liability, the valuation of share-based awards, the valuation of deferred tax assets and income tax uncertainties, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Cash
Cash
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
3332000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
41000
CY2021Q3 dawn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2646000
CY2020Q4 dawn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1259000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
173000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
43000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6151000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1343000
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
298000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
751000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
717000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
185000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
27000
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5161000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1596000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
281000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
267000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
62000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
77000
CY2021Q3 dawn Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2331000
CY2020Q4 dawn Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
554000
CY2021Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1894000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
51000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
212000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
18000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61928939
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61928939
CY2020Q4 dawn Number Of Directors Entitled To Be Elected By The Holders Of Common Stock
NumberOfDirectorsEntitledToBeElectedByTheHoldersOfCommonStock
1
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6035869
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6035869
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6972000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5149000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8224000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
176000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-19240000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-3842000
us-gaap Profit Loss
ProfitLoss
-50816000
us-gaap Profit Loss
ProfitLoss
-8243000
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1018000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2109000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2113000
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
99994000
CY2021Q3 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-19240000
CY2020Q3 dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-2824000
dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-148701000
dawn Net Income Loss Available To Common Stockholders Basic Not Affecting Cumulative Losses
NetIncomeLossAvailableToCommonStockholdersBasicNotAffectingCumulativeLosses
-6130000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.98
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57514218
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5601511
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29859883
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5456733
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9036632000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6399990000
CY2021Q2 dawn Adjustment To Additional Paid In Capital Loss On Conversion Of Temporary Equity Into Permanent Equity
AdjustmentToAdditionalPaidInCapitalLossOnConversionOfTemporaryEquityIntoPermanentEquity
100000000.0

Files In Submission

Name View Source Status
0000950170-21-003496-index-headers.html Edgar Link pending
0000950170-21-003496-index.html Edgar Link pending
0000950170-21-003496.txt Edgar Link pending
0000950170-21-003496-xbrl.zip Edgar Link pending
dawn-20210930.htm Edgar Link pending
dawn-20210930.xsd Edgar Link pending
dawn-20210930_cal.xml Edgar Link unprocessable
dawn-20210930_def.xml Edgar Link unprocessable
dawn-20210930_htm.xml Edgar Link completed
dawn-20210930_lab.xml Edgar Link unprocessable
dawn-20210930_pre.xml Edgar Link unprocessable
dawn-ex31_1.htm Edgar Link pending
dawn-ex31_2.htm Edgar Link pending
dawn-ex32_1.htm Edgar Link pending
dawn-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img10798652_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending